Hayward, California – January 25, 2013 – Advanced Cell Diagnostics, Inc., a world leader in the field of in situ nucleic acid detection for life science research and clinical diagnostics, today announced the appointment of Evangeline Gonzalez to its executive leadership team as Chief Commercial Officer. In this role, Mrs. Gonzalez will lead the company’s global commercialization efforts.
Mrs. Gonzalez will report directly to Advanced Cell Diagnostics CEO, Yuling Luo, Ph.D. “It was the breakthrough technology and the multi-talented team that attracted me to Advanced Cell Diagnostics. I’m so excited to join the team to help grow the company to the next level”.
Mrs. Gonzalez said. Mrs. Gonzalez has more than 17 years of commercialization experience in the biotechnology industry. She joins Advanced Cell Diagnostics from Life Technologies (formerly Applied Biosystems and Invitrogen), a 3.7 billion dollar company, where she was most recently Chief Marketing Officer of the Life Sciences Division. In this role, she was responsible for facilitating growth, marketing and global market development strategy. Previously she was Vice President of Market Development and Product Management for several businesses within Life Technologies including Protein Analysis, Sequencing and Molecular Biology Systems. In these roles, she was responsible for driving revenue growth for both existing products and commercializing new breakthrough technologies globally.
“Advanced Cell Diagnostics has achieved several important milestones over the last 3 months including closing a $12 million financing round, successfully introducing our automated RNAscope solution and expanding our commercial team.,” said Dr. Luo, “Evangeline’s proven track record of commercializing new technologies and her leadership skills are exactly what we need at this phase of our company’s growth,” Dr. Luo continued.
About Advanced Cell Diagnostics
Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell and tissue-based diagnostic tests for personalized medicine. The company’s products and services are based on its proprietary RNAscope® technology, the first multiplex chromogenic and fluorescent in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity. RNAscope assays are currently used by hundreds of customers, including all of the global top 10 pharmaceutical companies, world leading academic institutions and many cutting edge biotechnology companies to validate biomarkers for the management of cancer and other diseases. ACD’s industrial partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners’ targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope technology at www.acdbio.com